Gossamer Bio’s (GOSS) “Buy” Rating Reiterated at HC Wainwright

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $5.00 price objective on the stock.

Several other research firms have also recently commented on GOSS. The Goldman Sachs Group cut Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Wedbush restated a “neutral” rating and set a $1.00 target price (down from $6.00) on shares of Gossamer Bio in a research report on Tuesday, February 24th. Barclays cut Gossamer Bio from an “overweight” rating to an “underweight” rating in a research report on Tuesday, February 24th. Royal Bank Of Canada upgraded Gossamer Bio to an “outperform” rating in a research report on Tuesday, February 24th. Finally, Leerink Partners cut Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Four equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $5.00.

Gossamer Bio Stock Performance

NASDAQ:GOSS opened at $0.21 on Tuesday. Gossamer Bio has a 52-week low of $0.16 and a 52-week high of $3.87. The firm has a market cap of $49.31 million, a price-to-earnings ratio of -0.27 and a beta of 2.15. The business’s fifty day moving average is $0.36 and its 200 day moving average is $1.74.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings data on Monday, May 18th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $16.96 million during the quarter, compared to the consensus estimate of $4.67 million. Equities analysts predict that Gossamer Bio will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Gossamer Bio

Hedge funds and other institutional investors have recently modified their holdings of the company. Legal & General Group Plc purchased a new position in shares of Gossamer Bio in the 2nd quarter worth about $26,000. Banco BTG Pactual S.A. purchased a new stake in Gossamer Bio during the 2nd quarter valued at about $27,000. MMA Asset Management LLC purchased a new stake in Gossamer Bio during the 4th quarter valued at about $31,000. Soltis Investment Advisors LLC purchased a new stake in Gossamer Bio during the 4th quarter valued at about $31,000. Finally, Beacon Pointe Advisors LLC purchased a new stake in Gossamer Bio during the 4th quarter valued at about $34,000. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.